for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adverum Biotechnologies Inc

ADVM.OQ

Latest Trade

9.86USD

Change

0.09(+0.92%)

Volume

179,443

Today's Range

9.54

 - 

9.90

52 Week Range

2.81

 - 

16.38

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.77
Open
9.78
Volume
179,443
3M AVG Volume
42.46
Today's High
9.90
Today's Low
9.54
52 Week High
16.38
52 Week Low
2.81
Shares Out (MIL)
64.59
Market Cap (MIL)
631.03
Forward P/E
-9.65
Dividend (Yield %)
--

Next Event

Adverum Biotechnologies Inc at Piper Jaffray Healthcare Conference

Latest Developments

More

Adverum Biotechnologies Reports Q3 Loss Per Share Of $0.25

Adverum Biotechnologies Q2 Loss Per Share $0.23

Adverum Biotechnologies Provides Update On Optic Phase 1 Trial For Advm-022 In Wet AMD

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.

Industry

Biotechnology & Drugs

Contact Info

1035 Obrien Dr

+1.650.6569323

https://adverum.com/

Executive Leadership

C. Patrick Machado

Independent Chairman of the Board

Leone D. Patterson

Chief Executive Officer, Director

Thomas Leung

Chief Financial Officer

Aaron Osborne

Chief Medical Officer

Peter Soparkar

Chief legal officer

Key Stats

2.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3.140

2017

-1.290

2018

-1.180

2019(E)

-1.013
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,971.95
Price To Book (MRQ)
3.84
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-30.34
Return on Equity (TTM)
-28.38

Latest News

Latest News

BRIEF-Adverum Biotechnologies Reports Q1 Loss Per Share $0.30

* ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Adverum Biotechnologies Announces Leadership Changes

* BOARD AND AMBER SALZMAN, CHIEF EXECUTIVE OFFICER MADE A MUTUAL DETERMINATION THAT SALZMAN STEP DOWN

BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD

* ADVERUM BIOTECHNOLOGIES ANNOUNCES LONG-TERM PRECLINICAL EFFICACY DATA ON ADVM-022 GENE THERAPY IN WET AMD

BRIEF-Adverum Biotechnologies Q4 Loss Per Share $0.32

* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Adverum Biotechnologies Prices $60 Mln Public Offering Of Stock

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PRICING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Adverum Biotechnologies Announces Proposed Public Offering

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine

* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC

BRIEF-Adverum Biotechnologies Provides 2018 Outlook

* ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017.

BRIEF-Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies

* HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING Source text for Eikon: (http://bit.ly/2iwSEnw) Further company coverage:

BRIEF-Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial

* ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY

BRIEF-‍Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017

* ADAGE CAPITAL PARTNERS GP, L.L.C REPORTS A 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF NOVEMBER 17, 2017 - SEC FILING Source text: (http://bit.ly/2hXgpom) Further company coverage:

BRIEF-Adverum Biotechnologies posts Q3 loss of $0.32 per share

* Adverum biotechnologies reports third quarter 2017 financial results and provides corporate update

BRIEF-Adverum Biotechnologies says has increased size of board to eight members

* Adverum Biotechnologies Inc - increased size of board to eight members - SEC filing Source text: [http://bit.ly/2eKPWc0] Further company coverage:

BRIEF-Adverum Biotechnologies files for mixed shelf of up to $150 mln

* Adverum Biotechnologies Inc files for mixed shelf of up to $150 million - sec filing Source text: (http://bit.ly/2wyLc11) Further company coverage:

BRIEF-Adverum Biotechnologies Q2 loss per share $0.27

* Adverum Biotechnologies reports second quarter 2017 financial results and provides update

BRIEF-Adverum Biotechnologies Q1 loss per share $0.38

* Adverum Biotechnologies reports first quarter 2017 financial results and provides update

BRIEF-Adverum Biotechnologies on March 16, reached agreement in principle to settle consolidated securities class action lawsuit

* Adverum Biotechnologies- on March 16, reached agreement in principle to settle consolidated securities class action lawsuit

BRIEF-Adverum Biotechnologies Q4 loss per share $0.54

* Adverum Biotechnologies reports fourth quarter and full year 2016 financial results and provides update

BRIEF-Adverum Biotechnologies says Q3 loss per share $0.35

* Adverum Biotechnologies, Inc. reports third quarter 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up